Philipp E, Kapp W
Br J Clin Pharmacol. 1983;16 Suppl 1(Suppl 1):161S-165S. doi: 10.1111/j.1365-2125.1983.tb02289.x.
A double-blind study was conducted in 60 female patients with moderate or severe insomnia, hospitalized for gynaecological surgery. After an initial 2-day placebo selection phase, 30 subjects received 15 mg midazolam and the remaining 30 received 1 tablet Vesparax (= 50 mg hydroxyzine, 150 mg secobarbital, 50 mg brallobarbital) for 5 nights. This verum phase was immediately followed by a 2-day placebo withdrawal phase in order to study the occurrence of rebound phenomena. Both verum compounds were effective in hastening sleep onset, increasing sleep duration, and improving sleep quality, without causing residual effects on the following day. There was no difference in effect between the two agents. Neither active drug caused rebound effects on withdrawal.
对60名因妇科手术住院的中度或重度失眠女性患者进行了一项双盲研究。在最初为期2天的安慰剂筛选阶段后，30名受试者接受15毫克咪达唑仑，其余30名受试者接受1片Vesparax（=50毫克羟嗪、150毫克速可巴比妥、50毫克溴异戊巴比妥），持续5个晚上。在这个验证阶段之后紧接着是为期2天的安慰剂撤药阶段，以研究反弹现象的发生情况。两种受试药物在加快入睡、延长睡眠时间和改善睡眠质量方面均有效，且不会对次日造成残留影响。两种药物的效果没有差异。两种活性药物在撤药时均未引起反弹效应。
